Skip to main content

Table 3 Treatment duration and maintenance treatment duration

From: Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy

Treatment duration

N = 30

Months, median (95% CI)

7.9 (6.3–11.4)

Cycles, median (range)

11 (3–32)

Patients on treatment >6 months, n (%)

21 (70)

Patients on treatment >1 year, n (%)

7 (23.3)

Maintenance treatment duration

N = 24

Months, median (95% CI)

6.9 (3.0–9.8)

Patients on maintenance treatment >6 months, n (%)

11 (36.7)

Patients on maintenance treatment >1 year, n (%)

2 (6.7)